Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3637-3642

  Zhao, Deping ^a,c   Lu, Yi ^b   Yang, Chenlu ^c   Zhou, Xiao ^c   Xu, Zhifei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Thoracic Surgery Pudong District People s Hospital   (China)

^c SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

A549; ERK MAPK; Fibroblast growth factor receptor 1; JNK; MMP26; Non small cell lung cancer (NSCLC); PI3K

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MATRIX METALLOPROTEINASE 26; MITOGEN ACTIVATED PROTEIN KINASE; PD161570; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RECOMBINANT FIBROBLAST GROWTH FACTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; FGFR1 PROTEIN, HUMAN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MMP26 PROTEIN, HUMAN;

A549 CELL LINE; ARTICLE; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOGENESIS; METASTASIS POTENTIAL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASES, SECRETED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION;

EID: 84929964490     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-3001-y     Document Type: Article

References (29)

1. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (nsclc). J Thorac Dis. 2013;5:S389–96.
2. Mitsudomi T, Suda K, Yatabe Y. Surgery for nsclc in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.
3. Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of nsclc. Lung Cancer. 2013;80:120–30.
4. Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits mmp9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35:11051–6.
5. Pei J, Lou Y, Zhong R, Han B. Mmp9 activation triggered by epidermal growth factor induced foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.
6. Takaishi H, Kimura T, Dalal S, Okada Y, D’Armiento J. Joint diseases and matrix metalloproteinases: a role for mmp-13. Curr Pharm Biotechnol. 2008;9:47–54.
7. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (mmp-1, mmp-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157–64.
8. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (mmp-13) in human malignant tumors. APMIS. 1999;107:45–53.
9. Li D. Peaking of mmp-26 and timp-4 marks invasive transition in prostate cancer. Cell Res. 2006;16:741.
10. Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (mmp-26) expression with tumor progression and activation of mmp-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353–60.
11. Zhang Y, Zhao H, Wang Y, Lin Y, Tan Y, Fang X, et al. Non-small cell lung cancer invasion and metastasis promoted by mmp-26. Mol Med Rep. 2011;4:1201–9.
12. Li L, Mei TH, Zhou XD, Zhang XG. Expression and clinical significance of matrix metalloproteinase (mmp)-26 protein in non-small cell lung cancer. Ai Zheng. 2009;28:60–3.
13. Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost. 1999;82:748–54.
14. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta. 1992;1135:185–99.
15. Fujimoto J, Hori M, Ichigo S, Tamaya T. Expressions of the fibroblast growth factor family (fgf-1, −2 and −4) mrna in endometrial cancers. Tumour Biol. 1996;17:226–33.
16. Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires mapk/erk signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30:6595–606.
17. Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through mek-erk is required for prostate bud induction. Differentiation. 2007;75:638–51.
18. Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38mapk and up-regulation of the death receptor p75ntr. J Biol Chem. 2004;279:47912–28.
19. Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.
20. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the fgfr pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–63.
21. Parker BC, Engels M, Annala M, Zhang W. Emergence of fgfr family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 2014;232:4–15.
22. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable fgfr gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.
23. Beau-Faller M, Gaub MP, Schneider A, Guerin E, Meyer N, Ducrocq X, et al. Allelic imbalance at loci containing fgfr, fgf, c-met and hgf candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer. 2003;39:2538–47.
24. Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, et al. Novel fgfr inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing fgfr1. Oncol Rep. 2013;29:2181–90.
25. Volm M, Koomagi R, Mattern J, Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (fgfr-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 1997;33:691–3.
26. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type ii alveolar epithelial cells. Int J Cancer. 1976;17:62–70.
27. Kang M, Choi S, Jeong SJ, Lee SA, Kwak TK, Kim H, et al. Cross-talk between tgfbeta1 and egfr signalling pathways induces tm4sf5 expression and epithelial-mesenchymal transition. Biochem J. 2012;443:691–700.
28. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.
29. Xu Y, Xia W, Baker D, Zhou J, Cha HC, Voorhees JJ, et al. Receptor-type protein tyrosine phosphatase beta (rptp-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (hgfr/met) function. J Biol Chem. 2011;286:15980–8.